PAK4 as a Potential Marker for Poor Response to Immunotherapy in Melanoma Patients - Biognosys

PAK4 as a Potential Marker for Poor Response to Immunotherapy in Melanoma Patients

Posters

Poster presented at ESMO 2022

 
Authors: Mitchell P. Levesque, Nigel Beaton, Kristina Beeler, Judy Kuo, Harry Nunns, Tobias Treiber, Julia Martinez Gomez, Jakob Vowinckel, and Anna Juncker-Jensen
Presenter: Mitchell P. Levesque (University of Zurich, Switzerland)

Date: September 10

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    New: Drug Target Validation

    Reveal Binding Sites with Structural Proteomics

    New: Drug Target Validation

    Reveal Compound Binding Sites with Structural Proteomics

    Learn More